UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital — Birmingham, Alabama

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital is a clinical research site located in Birmingham, Alabama, United States 35233.

Crixeo Health Trust Score: 58/100 (POOR). This profile has not yet been claimed by the site owner.

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: MTAP-deleted Solid Tumors, Advanced Solid Tumors, HER2 Mutation.

Sponsors: Bayer.

Sponsor Feasibility Report

Trust Score: 58/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital?

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital has a Crixeo Trust Score of 58/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital conducted?

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital has 2 clinical trials on record, with 2 currently active. Their work covers MTAP-deleted Solid Tumors, Advanced Solid Tumors, HER2 Mutation.

Is UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital accredited by Crixeo Health?

UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.